Canopy Growth opened lower at $0.59, compared with its previous close of $0.61. In the last trading session, the stock traded between $0.56 and $0.60. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Canopy Growth is now worth
$ 0.43
Resulting in a loss of
$ 99.57 (99.57%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.03 (-4.79%)
Day High
$0.60
Day Low
$0.56
Day Open
$0.59
Prev Close
$0.61
Volume
31,03,285
1W Return
-23.20%
1M Return
-24.01%
3M Return
-42.80%
6M Return
-48.57%
1Y Return
-52.00%
Market Cap ($ Mn)
244
PE Ratio
-
PB Ratio
0.94
PEG Ratio
-
ROE
-115.22%
ROCE
-52.84%
EPS (TTM)
$-0.10
1 Week
-23.20%
1 Month
-24.01%
3 Months
-42.80%
6 Months
-48.57%
9 Months
-46.17%
Canopy Growth Q2FY27 Results: Revenue up 22% to $81.4 million
Consolidated net revenue rose 22% YoY to $81.4 million in Q2FY27. International segment revenue expanded 141% to $12.3 million. Adjusted EBITDA loss narrowed to $2.9 million, improving sequentially. Storz & Bickel revenue declined 4% to $15.1 million due to weak consumer spending.
6 days agoCanopy Growth shareholders approve 1-for-5 to 1-for-15 share consolidation
Shareholders approved a share consolidation ratio of 1-for-5 to 1-for-15, subject to board discretion. MNP LLP appointed as auditor for fiscal year ending March 31, 2027. Voter turnout was 36.60%, with 154,837,897 shares voted. All board nominees elected, with support ranging from 84.88% to 89.18%.
17 days agoCanopy Growth appoints Sebastian Blöte as Germany country manager
Sebastian Blöte appointed as Country Manager for Germany effective October 1, 2026. Role focuses on expanding sales and strengthening execution in the German medical cannabis market. Blöte brings over a decade of experience including roles at a leading German medical cannabis company. Canopy Growth reported double-digit sequential growth in international medical cannabis for three consecutive quarters.
1mo agoCanopy Growth adjourns 2026 AGM due to lack of quorum
Canopy Growth adjourned its 2026 AGM on September 25, 2026, due to lack of quorum. The meeting reconvenes on October 23, 2026, with a new voting deadline of 9:00 am ET. Quorum requires 33 1/3% of outstanding shares to be present or represented by proxy. Shareholders of record as of July 31, 2026, remain eligible to vote.
1mo agoCanopy Growth expands UK medical cannabis supply via GROW Group deal
Canopy Growth will supply four Canadian-grown flower strains to GROW Group for UK distribution. Products will be commercialized under the Spectrum Therapeutics brand in the UK. Expansion relies on renewed EU GMP certification at the Kincardine, Ontario facility. GROW Group acts as the manufacturer and distributor for prescribed medicines in Europe.
1mo agoCanopy Gwth Q1FY27 Results: Revenue up 13%, gross margin expands
Net revenue rose 13% YoY to $81.2 million in Q1FY27. Adjusted gross margin expanded 600 bps to 31% from 25%. Canadian medical revenue grew 22% to $25.8 million. Storz & Bickel gross margin jumped to 48% from 29%. Cash position remains strong at $337 million.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Canopy Growth is now worth
$ 0.43
Resulting in a loss of
$ 99.57 (99.57%)
Note: Past profits do not guarantee future returns.
